Wednesday, November 25, 2009, 1:27am EST - Canadian Markets open in 8 hours and 3 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Nektar Therapeutics (NKTR)

 On Nov 24: 8.70 USD  Down 0.06 (0.68%)  
MORE ON NKTR
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Nektar Therapeutics (NasdaqNM:NKTR) Delayed quote dataEdit
After Hours: 8.70 0.00 (0.00%) as of 4:59pm EST on 11/24/09
Last Trade: 8.70 USD
Trade Time: Nov 24
Change: Down 0.06 (0.68%)
Prev Close: 8.76
Open: 8.76
Bid: 7.79 x 100
Ask: 9.60 x 100
1y Target Est: 10.55
Day's Range: 8.58 - 8.81
52wk Range: 3.90 - 10.64
Volume: 313,384
Avg Vol (3m): 759,258
Market Cap: 810.81M
P/E (ttm): N/A
EPS (ttm): -1.21
Div & Yield: N/A (N/A%)
Nektar Therapeutics (NKTR)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add NKTR to Portfolio   Download Data

HEADLINES
• Abbott: Brave or Stupid?
at Motley Fool (Fri, Nov 13)
• AstraZeneca Beats, Raises
Zacks.com (Fri, Nov 13)
• NEKTAR THERAPEUTICS Financials
EDGAR Online Financials (Tue, Nov 10)
• New Star Analyst Rankings for Nektar Therapeutics
StarMine (Thu, Nov 5)
• NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Nov 5)
• Nektar Therapeutics Financial Results Call scheduled for 5:00 pm ET today
CCBN (Wed, Nov 4)
• NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
EDGAR Online (Wed, Nov 4)
• Nektar Therapeutics Reports Third Quarter 2009 Financial Results
PRNewswire (Wed, Nov 4)
• Q3 2009 Nektar Therapeutics Earnings Release - Time Not Supplied
CCBN (Wed, Nov 4)
• Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
PRNewswire (Thu, Oct 29)
• Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer
PRNewswire (Wed, Oct 28)
More Headlines for NKTR...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices